<?xml version="1.0" encoding="utf-8" ?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>REDHILL BIOPHARMA 1 RSS Feed | Nachrichten - www.finanzen.net</title><description>www.finanzen.net bietet Finanznachrichten zum weltweiten Börsengeschehen</description><category>Finanzen</category><link>https://www.finanzen.net</link><language>de-de</language><copyright>finanzen.net GmbH</copyright><lastBuildDate>Thu, 18 Jun 2026 21:04:03 +0200</lastBuildDate><atom:link href="https://www.finanzen.net/rss/redhill%5Fbiopharma%5F1%2Drss%2Dfeed" rel="self" type="application/rss+xml"/><image><url>https://images.finanzen.net/images/finanzen_net_neu.gif</url><title>REDHILL BIOPHARMA 1 RSS Feed | Nachrichten - www.finanzen.net</title><link>https://www.finanzen.net</link></image><item><title>RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects</title><pubDate>Mon, 05 Jan 2026 13:00:00 +0100</pubDate><link>https://www.finanzen.net/nachricht/aktien/redhill-s-rhb-102-progresses-in-multiple-gi-indications-including-glp-1-therapy-related-gi-side-effects-15391987</link><description><![CDATA[<p><p class="prntac" xmlns="http://www.w3.org/1999/xhtml"><i>RHB-102</i><sup><i>1</i></sup><i> is a proprietary, advanced clinical-stage, once-daily, bimodal extended-release, oral tablet formulation of 5-HT3 antagonist, ondansetron, targeting oncology support,  ...</p>]]></description><guid isPermaLink="true">https://www.finanzen.net/nachricht/aktien/redhill-s-rhb-102-progresses-in-multiple-gi-indications-including-glp-1-therapy-related-gi-side-effects-15391987</guid></item></channel></rss>
